FDA panel: Theravance's Vibativ suitable when no alternatives in HAP Reported by Bloomberg. Theravance shares remain halted for trade as FDA panel votes on Theravance drug for expanded indication to treat Hospital-acquired pneumonia, or HAP.
News For THRX From The Last 14 Days
Check below for free stories on THRX the last two weeks.
Theravance, GlaxoSmithKline receive Australian approval for Breo Ellipta GlaxoSmithKline (GSK) and Theravance (THRX) announced that the Therapeutic Goods Administration has approved BREO ELLIPTA for the treatment of patients with asthma or chronic obstructive pulmonary disease, or COPD, in Australia. Two strengths of BREO ELLIPTA have been licensed for the treatment of asthma and one strength has been licensed for the treatment of COPD.